Acquisition Pending

Zymeworks acquisition of Theravance Biopharma

US$929m consideration

Announced 29 Jun 2026 · NASDAQ: TBPH · US$17.00 cash and scrip per share

Advisers

Theravance Biopharma

Target

Financial adviser
Fairness opinion

Zymeworks

Acquirer

Financial adviser
Legal adviser
Tax adviser

Other advisers

Financial adviser
Target
Theravance Biopharma
Acquirer
Zymeworks
Target based in
United States
Buyer based in
United States
Sector
Pharma
Tags
Pharma, Biotech

In the league tables

Similar deals

All pharma deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.